NewAmsterdam Pharma Company N.V.

NAMS

$23.32

Updated: 23/09/2026, 05:07:49

Market Cap

$2.73B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for NAMS

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

USD

NASDAQ

CEO: Michael Harvey Davidson Facp.

Employees: 100

https://www.newamsterdampharma.com

Asset Summaries

Latest generated summaries for NAMS

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for NAMS.

Share price: $23.32
Market cap: $2.73B
Exchange: NASDAQ
Currency: USD
CEO: Michael Harvey Davidson Facp.
Employees: 100
IPO date: 09/02/2021
Beta: 0.094
Last dividend: $0.00
Day range: $22.16 – $23.71
52-week range: $21.02 – $42.21
1-day performance: 3.28%
1-year performance: 10.94%
Current drawdown (1Y): -44.75%
CIK: 0001936258
CUSIP: N/A
ISIN: NL00150012L7
Created: 07/12/2025, 05:23:51
Last update: 23/09/2026, 05:07:49

Track NewAmsterdam Pharma Company N.V. with an AI analyst

See which prediction-market events move NAMS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to NAMS from your Railway `news_articles` table.

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 10/06/2026, 02:52:09

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 17:00:51

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

GlobeNewsWire • STOCK • 11/05/2026, 10:41:00

NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript

Seeking Alpha • STOCK • 09/05/2026, 22:03:52

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

GlobeNewsWire • STOCK • 23/03/2026, 09:00:00

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

GlobeNewsWire • STOCK • 04/02/2026, 09:00:00